Filing summary
Filing identity: The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2023—not Lite Strategy, Inc.’s 2022 Q1 filing as specified in the request metadata. The figures below summarize the filing text provided.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company. Its principal programs are voruciclib, an oral CDK9 inhibitor, and ME-344, an intravenous mitochondrial inhibitor. The quarter is the first quarter of fiscal 2024; comparisons are with the three months ended September 30, 2022. The company discontinued global zandelisib development with Kyowa Kirin (KKC) and regained global rights, subject to limited compassionate-use rights.
Key financial metrics
| Metric | Quarter ended September 30, 2023 | Prior-year quarter |
|---|---|---|
| Revenue | $65.3 million | $8.7 million |
| Operating expenses | $10.0 million | $26.9 million |
| Operating income (loss) | $55.3 million | ($18.2 million) |
| Net income (loss) | $56.4 million | ($16.6 million) |
| Net income (loss) per share, basic and diluted | $8.46 | ($2.49) |
| Net cash used in operating activities | $18.5 million | $14.8 million |
Revenue included $64.5 million of collaboration revenue recognized after termination of the KKC agreement, primarily from recognizing deferred revenue allocated to the U.S. license. This is a significant unusual, non-recurring item; the filing does not present the quarter’s net income as a measure of recurring operating performance. Customer revenue was $0.8 million, versus $8.7 million a year earlier.
Research and development expense was $3.5 million, down from $19.5 million, mainly reflecting zandelisib wind-down and reduced personnel costs; G&A was $6.5 million, down from $7.5 million. Interest and dividend income was $1.1 million, compared with $0.5 million.
At September 30, 2023, cash and cash equivalents were $3.4 million and short-term U.S. government investments were $78.8 million, or $82.2 million combined. Total assets were $101.3 million, total liabilities $19.9 million, and stockholders’ equity $81.4 million. The company reported no debt in the balance sheet presented. Operating lease liabilities totaled $12.4 million, with $15.8 million of undiscounted remaining lease payments. The company reported accumulated losses of $349.6 million.
Material changes versus the prior comparable period
- Revenue rose to $65.3 million, primarily because the KKC agreement termination triggered recognition of $64.5 million in previously deferred license revenue. Deferred revenue associated with the agreement was zero at quarter-end.
- Operating expenses fell by $16.9 million, principally due to the zandelisib discontinuation, workforce reductions and lower related costs.
- Net income turned positive because of the one-time collaboration revenue recognition; operating cash use increased to $18.5 million. The cash flow statement shows a $64.9 million reduction in deferred revenue and substantial reductions in accrued liabilities and accounts payable.
- Cash and cash equivalents declined from $16.9 million at June 30 to $3.4 million at September 30, while short-term investments declined from $83.8 million to $78.8 million.
Outlook, commentary, risks and unusual items
- Management said the $82.2 million of cash and short-term investments should fund operations for at least 12 months from issuance of the statements and through planned clinical data readouts. It expects operating losses and negative operating cash flows for the foreseeable future, expects R&D spending to increase, and anticipates needing future financing or partnerships; additional capital may not be available on acceptable terms.
- Voruciclib Phase 1 clinical data were expected early in calendar 2024. The completed monotherapy escalation enrolled 40 heavily pre-treated patients; management reported no dose-limiting toxicities on the selected intermittent schedule and a 50% disease-control rate among 10 AML patients treated at the highest evaluated dose. These are early-stage results, not proof of efficacy.
- ME-344 plus bevacizumab is being studied in a Phase 1b trial in relapsed colorectal cancer. Safety and efficacy data from the first cohort of 20 patients were expected in the first half of calendar 2024. A potential additional capital return of approximately $9.33 million may be considered if specified trial conditions are met or the Board decides not to proceed with a second cohort; it is subject to Board approval.
- Under an October 31, 2023 Cooperation Agreement with Anson Funds and Cable Car Capital, the company agreed to a $1.75-per-share cash dividend and reimbursement of investor fees and expenses up to $1.2 million. The Board declared the dividend on November 6, payable December 6, 2023, to holders of record November 17. Three directors resigned and investor-designated directors joined the Board.
- The company adopted a stockholder rights agreement on October 1, 2023. Management identified clinical-trial, regulatory, financing, collaboration, manufacturing, intellectual-property and market risks. It reported no material change in risk factors from its latest annual report, no material pending litigation, and effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Confirm the requested issuer and reporting period: the supplied text is MEI Pharma’s September 30, 2023 quarter, not Lite Strategy’s 2022 Q1.
- Review the KKC termination accounting and distinguish the $64.5 million non-recurring revenue recognition from ongoing revenue and cash generation.
- Track operating cash use, clinical spending, and management’s stated 12-month funding runway, especially after the declared dividend and any further capital return.
- Check actual timing and results of the voruciclib and ME-344 readouts, and the trial criteria governing any additional return of capital.
- Assess the remaining lease commitments, potential Presage milestone and royalty obligations, and the company’s ability to raise future capital.